Healthcare entity
Every one of those 1 sits in a single category, funding. James E. Dentzer is most often covered alongside Caleres, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.3.
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, funding. James E. Dentzer is most often covered alongside Caleres, which appears in 1 of these 1 story. At 5, the average consequence score sits below the same-window beat average of 6.3. They are better corroborated than the beat average, carrying 4 original sources each against 2.9 for the same window. We currently track 1 Healthcare story that mention James E. Dentzer, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering James E. Dentzer. Shared-story counts are live from our verified record — not editorial picks.
ASH Annual Meeting
Curis targets presentation of initial proof-of-concept data for the CLL study.
Torrid Store Closures
Target date for an additional 30 store closures by Torrid to reach savings goals.
Q4 Earnings Release
Curis, Torrid, Caleres, and Lands' End all report Q4 2025 results.
PIPE Financing
Curis secured initial $20.2M in PIPE proceeds to fund oncology pipeline development.
Erivedge Wind-down
Royalties from Erivedge began winding down, prompting the strategic sale to Oberland.
Curis (CRIS) has successfully pivoted to a clinical-stage oncology focus, securing a cash runway into 2027 through a strategic asset sale and PIPE financing. Meanwhile, broader retail earnings from Torrid and Caleres reveal significant margin pressures from tariffs, signaling a complex macro environment for healthcare supply chains.
Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)
James E. Dentzer is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
